MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Chorea (also see specific diagnoses, Huntingtons disease, etc): Treatment"

  • 2025 International Congress

    Developing a Framework for Huntington’s Disease Care Partner Training and Support – HD Care Partner Bootcamp Series

    J. Yomtoob, E. Zivin, K. Fagan, D. Bega (Chicago, USA)

    Objective: In this protocol we present a novel collaborative framework for a Huntington’s Disease (HD) Care Partner (CP) bootcamp series designed to train and support…
  • 2025 International Congress

    A mindfulness-based intervention course in pre-manifest Huntington’s disease: analysis of pilot data

    S. Berman, R. Devenyi, V. Vaughn, G. Toti, A. Lasker (Camden, USA)

    Objective: To assess feasibility and initial outcomes of a mindfulness-based intervention course in patients with pre-manifest, genetically confirmed Huntington’s disease (HD). Background: Mindfulness-based intervention courses…
  • 2025 International Congress

    Patient Experience and Satisfaction With Once-Daily Deutetrabenazine Extended-Release Tablets for Treatment of Huntington Disease-Related Chorea

    B. Bulica, M. Konings, S. Thompson, A. Yang, S. Kotak, P. Gandhi (Detroit, USA)

    Objective: Objectives of this study were to explore patient-reported ease of use, effectiveness, and satisfaction during real-world use of once-daily (QD) deutetrabenazine extended-release tablets in…
  • 2025 International Congress

    Valbenazine Improves Chorea Across Multiple Body Regions in Adults With Huntington’s Disease

    E. Furr Stimming, E. Kayson, R. Mehanna, J. Goldstein, S. Hinton, O. Klepitskaya, H. Zhang, D. Haubenberger (Houston, USA)

    Objective: To evaluate valbenazine’s effects on chorea across body regions in adults with Huntington’s disease (HD) using data from KINECT®-HD (NCT04102579). Background: Once-daily valbenazine is…
  • 2025 International Congress

    Decreased Disease Burden in Motor-Related HD-HI Domains Among Adults With Huntington’s Disease Treated With Valbenazine

    E. Furr Stimming, H. Zhang, O. Klepitskaya, D. Haubenberger, S. Hinton, C. Heatwole (Houston, USA)

    Objective: To evaluate the effects of valbenazine (VBZ) on mobility, abnormal movements, and hand/arm function as assessed using the Huntington’s Disease Health Index (HD-HI). Background:…
  • 2025 International Congress

    Long-Term Safety and Efficacy of Valbenazine for Treating Huntington’s Disease Chorea

    E. Furr Stimming, E. Kayson, S. Karpuram, J. Goldstein, S. Hinton, O. Klepitskaya, H. Zhang, E. Dunayevich, D. Haubenberger (Houston, USA)

    Objective: To present safety and efficacy results from a long-term study of once-daily valbenazine for chorea associated with Huntington’s disease (HD). Background: In a 12-week…
  • 2025 International Congress

    Long-term results of pallidal deep brain stimulation in patients with Huntington’s disease

    A. Gamaleya, A. Poddubskaya, S. Asriyants, A. Tomskiy (Moscow, Russian Federation)

    Objective: To analyze long-term results of pallidal (GPi) deep brain stimulation (DBS) in patients with Huntington's disease (HD). Background: In HD, DBS is suggested to…
  • 2025 International Congress

    Analysis of Emergency Department Encounters and Hospital Admissions of People with Huntington’s Disease

    T. Orem, E. Forbes, S. Sillau (Aurora, USA)

    Objective: Define characteristics of emergency department encounters and hospital admissions of people with Huntington’s disease and identify opportunities for intervention to reduce hospitalizations. Background: Huntington’s…
  • 2025 International Congress

    Efficacy and Safety of Deutetrabenazine in Huntington’s Disease: a Systematic Review

    A. Viapiana, V. Müller, L. Lima, A. Petry, R. Juvêncio, A. Ribeiro, D. Gonçalves, M. da Rosa, G. Maia, V. Xavier (Porto Alegre, Brazil)

    Objective: To evaluate efficacy and safety of deutetrabenazine (DTB) in Huntington's Disease (HD) in order to guide evidence-based clinical decisions. Background: HD is a genetic…
  • 2025 International Congress

    Safety, Feasibility, and Effects of Time-Restricted Eating in Early-Stage Huntington’s Disease: Preliminary Analysis of a Clinical Pilot Trial

    R. Wells, L. Neilson, A. Hiller (Portland, USA)

    Objective: Evaluate whether 12 weeks of daily time-restricted eating (TRE) appears safe and feasible in persons with early-stage Huntington's disease (HD) and explore its effects…
  • 1
  • 2
  • 3
  • …
  • 11
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
    • Life expectancy with and without Parkinson’s disease in the general population
    • Effect of marijuana on Essential Tremor: A case report
    • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
    • Covid vaccine induced parkinsonism and cognitive dysfunction
    • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
    • Patients with Essential Tremor Live Longer than their Relatives
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley